Eli Lilly and Company (LLY) : During the past 4 weeks, traders have been relatively bearish on Eli Lilly and Company (LLY), hence the stock is down -3.47% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.42% relative to the S&P 500. The 4-week change in the price of the stock is -3.1% and the stock has fallen -1.45% in the past 1 week.
Eli Lilly and Company is up 6.35% in the last 3-month period. Year-to-Date the stock performance stands at -4.28%. The stock has recorded a 20-day Moving Average of 2.71% and the 50-Day Moving Average is 0.84%.
Eli Lilly and Company (NYSE:LLY): The stock opened at $79.55 on Friday but the bulls could not build on the opening and the stock topped out at $79.79 for the day. The stock traded down to $78.78 during the day, due to lack of any buying support eventually closed down at $79.06 with a loss of -0.90% for the day. The stock had closed at $79.78 on the previous day. The total traded volume was 3,746,012 shares.
Also, Equity Analysts at the Argus Research maintains the rating on Eli Lilly and Company (NYSE:LLY). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $90 per share to $95 per share. The rating by the firm was issued on August 2, 2016.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.